ELVN
NASDAQ HealthcareEnliven Therapeutics, Inc. - Common Stock
Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
�� 市场数据
| 价格 | $48.11 |
|---|---|
| 成交量 | 1,363,077 |
| 市值 | 2.88B |
| 贝塔系数 | 0.490 |
| RSI（14日） | 70.8 超买 |
| 200日均线 | $23.77 |
| 50日均线 | $32.98 |
| 52周最高 | $48.53 |
| 52周最低 | $14.79 |
| Forward P/E | -18.94 |
| Price / Book | 6.22 |
🎯 投资策略评分
ELVN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (47/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ELVN in your text
粘贴任何文章、记录或帖子 — 工具将提取 ELVN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.